Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 9c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.21), $0.09 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $35.54 million versus the consensus estimate of $24.51 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Benchmark initiates Synopsys, Cadence with Buy ratings on AI-driven EDA outlook
• Cintas (CTAS) PT Raised to $230 at UBS Following Q4 Results, Guidance
• Natural Gas Inventory 41 bcf vs 41 bcf Expected